Yield10 Bioscience Stock Forecast, Price & News

-0.31 (-4.04 %)
(As of 07/29/2021 02:52 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume300 shs
Average Volume150,970 shs
Market Capitalization$35.88 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive YTEN News and Ratings via Email

Sign-up to receive the latest news and ratings for Yield10 Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Yield10 Bioscience logo

About Yield10 Bioscience

Yield10 Bioscience, Inc. operates as an agricultural bioscience company. It focuses on the development of technologies to produce step-change improvements in crop yield for food and feed crops to enhance global food security. The company was founded by Anthony J. Sinskey, Simon F. Williams and Oliver P. Peoples in June 1992 and is headquartered in Woburn, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.49 out of 5 stars

Consumer Staples Sector

135th out of 330 stocks

Miscellaneous Plastics Products Industry

2nd out of 4 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Yield10 Bioscience (NASDAQ:YTEN) Frequently Asked Questions

Is Yield10 Bioscience a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Yield10 Bioscience in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Yield10 Bioscience stock.
View analyst ratings for Yield10 Bioscience
or view top-rated stocks.

What stocks does MarketBeat like better than Yield10 Bioscience?

Wall Street analysts have given Yield10 Bioscience a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Yield10 Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Yield10 Bioscience?

Yield10 Bioscience saw a increase in short interest in July. As of July 15th, there was short interest totaling 73,200 shares, an increase of 27.7% from the June 30th total of 57,300 shares. Based on an average trading volume of 64,200 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.9% of the shares of the stock are sold short.
View Yield10 Bioscience's Short Interest

When is Yield10 Bioscience's next earnings date?

Yield10 Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for Yield10 Bioscience

How were Yield10 Bioscience's earnings last quarter?

Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced its quarterly earnings data on Monday, May, 10th. The specialty chemicals company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.14. The specialty chemicals company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.25 million. Yield10 Bioscience had a negative net margin of 1,123.41% and a negative trailing twelve-month return on equity of 69.20%.
View Yield10 Bioscience's earnings history

How has Yield10 Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Yield10 Bioscience's stock was trading at $4.82 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, YTEN shares have increased by 52.9% and is now trading at $7.37.
View which stocks have been most impacted by COVID-19

When did Yield10 Bioscience's stock split? How did Yield10 Bioscience's stock split work?

Yield10 Bioscience's stock reverse split before market open on Thursday, January 16th 2020. The 1-40 reverse split was announced on Wednesday, January 15th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2020. An investor that had 100 shares of Yield10 Bioscience stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for YTEN?

3 Wall Street analysts have issued 12 month price targets for Yield10 Bioscience's shares. Their forecasts range from $15.00 to $25.00. On average, they expect Yield10 Bioscience's share price to reach $21.33 in the next twelve months. This suggests a possible upside of 189.5% from the stock's current price.
View analysts' price targets for Yield10 Bioscience
or view top-rated stocks among Wall Street analysts.

Who are Yield10 Bioscience's key executives?

Yield10 Bioscience's management team includes the following people:
  • Oliver P. Peoples, President, Chief Executive Officer & Director
  • Charles B. Haaser, Chief Accounting Officer, Treasurer & VP-Finance
  • Kristi D. Snell, Chief Science Officer & Vice President-Research
  • Nicholas Renegar, Director-Business Analytics & Operations
  • Lynne H. Brum, Secretary, VP-Planning & Communications

Who are some of Yield10 Bioscience's key competitors?

What other stocks do shareholders of Yield10 Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Yield10 Bioscience investors own include KushCo (KSHB), (CGC), OPKO Health (OPK), T2 Biosystems (TTOO), FuelCell Energy (FCEL), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Rigel Pharmaceuticals (RIGL), (SCON) and Advanced Micro Devices (AMD).

What is Yield10 Bioscience's stock symbol?

Yield10 Bioscience trades on the NASDAQ under the ticker symbol "YTEN."

How do I buy shares of Yield10 Bioscience?

Shares of YTEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Yield10 Bioscience's stock price today?

One share of YTEN stock can currently be purchased for approximately $7.37.

How much money does Yield10 Bioscience make?

Yield10 Bioscience has a market capitalization of $35.88 million and generates $800,000.00 in revenue each year. The specialty chemicals company earns $-10,210,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis.

How many employees does Yield10 Bioscience have?

Yield10 Bioscience employs 25 workers across the globe.

What is Yield10 Bioscience's official website?

The official website for Yield10 Bioscience is

Where are Yield10 Bioscience's headquarters?

Yield10 Bioscience is headquartered at 19 PRESIDENTIAL WAY, WOBURN MA, 01801.

How can I contact Yield10 Bioscience?

Yield10 Bioscience's mailing address is 19 PRESIDENTIAL WAY, WOBURN MA, 01801. The specialty chemicals company can be reached via phone at (617) 583-1700 or via email at [email protected]

This page was last updated on 7/29/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.